BCTXW
BriaCell Therapeutics Corp.
Key Financials
Operating Income
$-27204803
↑ 18.4%
Net Income
$-26311867
↓ 449.1%
EPS (Diluted)
$-62.19
↓ 21344.8%
Total Assets
$21.6M
↑ 268.7%
Shareholders' Equity
$-3777181.00
↓ 136.6%
Cash & Equivalents
$10.5M
↑ 1117.3%
Operating Cash Flow
$-28170520.00
↓ 16.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 3/31/2026 | View on SEC |
| 10-Q | 3/10/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| 25-NSE | 2/26/2026 | View on SEC |
| 8-K | 2/20/2026 | View on SEC |
| DEF 14A | 2/12/2026 | View on SEC |
| SCHEDULE 13G | 1/23/2026 | View on SEC |
| 8-K | 1/15/2026 | View on SEC |
| 424B4 | 1/14/2026 | View on SEC |
| EFFECT | 1/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BCTXW |
| Company Name | BriaCell Therapeutics Corp. |
| CIK | 1610820 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0731 |
| State of Incorporation | A1 |
| Phone | (604) 921-1810 |